Inhibition of CYP isoforms by mirtazapine
| CYP Isoform | Index Reaction | Substrate Concentration | Mean (S.D.) % of Control Activity at MIR Concentrations [μM]3-a | |||
|---|---|---|---|---|---|---|
| 25 | 50 | 100 | 250 | |||
| μM | % | |||||
| 1A2 | Phenacetin-O-deethylation | 100 | 97.8 (1.7) | 97.0 (3.7) | 91.2 (2.1) | 81.6 (2.2) |
| 2C9 | Tolbutamide-hydroxylation | 100 | 96.1 (4.2) | 89.6 (7.4) | 84.0 (4.9) | 68.9 (3.6) |
| 2C19 | S-mephenytoin-hydroxylation | 25 | 95.6 (6.7) | 91.3 (4.1) | 91.8 (7.0) | 88.5 (6.7) |
| 2D6 | Dextromethorphan-O-demethylation | 25 | 86.6 (8.7) | 71.7 (6.8) | 57.5 (6.6) | 34.2 (0.6) |
| 2E1 | Chlorzoxazone-hydroxylation | 50 | 98.6 (4.3) | 99.4 (4.6) | 98.4 (5.0) | 99.4 (7.8) |
| 3A | Triazolam-4-hydroxylation | 250 | 57.6 (11.6) | 49.6 (13.8) | 35.9 (9.8) | 18.8 (4.7) |
↵3-a Values represent activity relative to control incubation without MIR.